About The Prize
The Scottish Cancer foundation invites nominations for the 2018 Prize which will be for Early Stage Researchers within 7 years of a PhD (excluding maternity leave) in any discipline working on an aspect of cancer prevention.
Criteria for the prize alternates each year between:
- Early Stage Researcher (2018)
- Education (2019)
- Public Engagement (2020)
Applicants may be nominated or be self nominated. The applicant must be living and working in Scotland at the time of the award. The nature of their contribution is not specified and the prize is open to anyone, in any discipline, working on an aspect of cancer prevention in Scotland, although evidence of wider impact would be welcomed.
The Prize, up to £10,000, is awarded annually at the Scottish Cancer Conference, and is supported by the Grant Simpson Trust. It is accompanied by the Evans Forrest Medal, named in recognition of the founders of the Scottish Cancer Foundation.
Professor Malcolm Dunlop of the MRC Human Genetics Unit, within the Institute of Genetics and Molecular Medicine at the University of Edinburgh, has led research which has identified a number of genes that are implicated in the development of bowel cancer. He plans to use the £10,000 prize money to investigate new drug and nutrient approaches that may reduce the risk of bowel cancer developing.
An anti-tobacco campaigner who has played a leading role in reducing the harm caused by cigarettes in Scotland has been honoured by the Scottish Cancer Foundation. Sheila Duffy, the chief executive of ASH Scotland, is this year’s recipient of Scottish Cancer Foundation prize which recognises individuals who have made an outstanding contribution in the fight against cancer.
Our inaugural prize was won by Professor Tessa Holyoake, a cancer specialist who has made Glasgow into one of the world’s leading centres for leukaemia research.
The work carried out by Professor Tessa Holyoake, Director of the Paul O’Gorman Leukaemia Research Centre at the University of Glasgow, is offering hope of new treatments for a condition which has already seen dramatic improvements in survival in recent years.